Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enliven Therapeutics (ELVN) EBITDA (2019 - 2026)

Enliven Therapeutics has reported EBITDA over the past 8 years, most recently at -$24.3 million for Q1 2026.

  • Quarterly results put EBITDA at -$24.3 million for Q1 2026, up 14.93% from a year ago — trailing twelve months through Mar 2026 was -$99.1 million (down 4.59% YoY), and the annual figure for FY2025 was -$103.4 million, down 16.05%.
  • EBITDA reached -$24.3 million in Q1 2026 per ELVN's latest filing, up from -$29.6 million in the prior quarter.
  • Across five years, EBITDA topped out at -$8.9 million in Q2 2022 and bottomed at -$29.6 million in Q4 2025.
  • Median EBITDA over the past 5 years was -$20.0 million (2024), compared with a mean of -$19.5 million.
  • The largest annual shift saw EBITDA soared 33.37% in 2022 before it tumbled 99.81% in 2023.
  • Over 5 years, EBITDA stood at -$9.5 million in 2022, then crashed by 99.81% to -$19.1 million in 2023, then fell by 22.46% to -$23.4 million in 2024, then dropped by 26.48% to -$29.6 million in 2025, then rose by 17.63% to -$24.3 million in 2026.
  • Business Quant data shows EBITDA for ELVN at -$24.3 million in Q1 2026, -$29.6 million in Q4 2025, and -$19.8 million in Q3 2025.